Full Press Release Details
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver
Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
CAMBRIDGE, Mass., December 9, 2024 (GLOBE NEWSWIRE) Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering
company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by MylotargTM. The data, which was presented in a poster at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 8th, demonstrated
durable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of improved relapse free survival compared to published high-risk AML comparators.
With additional maturity, we are even more encouraged by this data and the potential of offering AML and MDS patients the opportunity to receive
post-transplant maintenance therapy while still maintaining healthy blood count levels, said Dr. Eyal Attar, Vor Bio s Chief Medical Officer.
The data released today included 25 patients treated with trem-cel of which 15 had received Mylotarg (six at the
2 mg/m2 dose) as of the data cut-off date of November 1, 2024. The data demonstrated:
Company received supportive feedback from the FDA in a Type C
The Company had the opportunity to interact with the FDA regarding data from the trem-cel +
Mylotarg study alongside a proposed registrational clinical trial synopsis. The FDA agreed that trem-cel engrafts neutrophils and platelets and has a similar safety profile to unedited CD34+ grafts. In
addition, there was agreement with the trem-cel + Mylotarg registrational clinical trial design with respect to study population, control arm, primary endpoint, stratification factors, and statistical design.
The Company agreed to provide further updates to the FDA alongside submission of the full clinical trial protocol.
Conference Call & Webcast Information
Vor Bio management, joined by Guenther Koehne, MD, PhD, an investigator on the VBP101 study and Deputy Director and Chief of Blood &
Marrow Transplant and Hematologic Oncology at Miami Cancer Institute of Baptist Health South Florida, will host a live webcast
5:00 AM PT / 8:00 AM ET.
Listeners can register for the webcast via this LINK
Analysts wishing to participate in the Q&A session should use this LINK
A replay of the webcast will be available via the investor section of the Company s website
at www.vorbio.com approximately two hours after the call s conclusion.
Vor Bio is a clinical-stage cell and
genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Forward-Looking Statements
contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words aim, anticipate, can, continue, could, design,
enable, expect, initiate, intend, may, on-track, ongoing, plan, potential, should,
target, update, will, would, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking
statements in this press release include Vor Bio s statements regarding the potential of its product candidates to positively impact quality of life and alter the course of disease in the patients it seeks to treat, including potential
improvements in relapse-free survival, the timing of initiation of clinical trials, the potential of trem-cel to enable targeted therapies in the post-transplant setting including Mylotarg and CD33-targeted CAR-Ts while maintaining healthy blood count levels and change the standard of care for patients with blood cancers, the safety profile of trem-cel plus Mylotarg, the
potential design of a registrational trial for trem-cel and plans for regulatory submissions for trem-cel. Vor Bio may not actually achieve the plans, intentions, or
expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these
forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Vor Bio s product candidates; availability and
timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; uncertainties regarding regulatory approvals to
conduct trials or to market products; the success of Vor Bio s in-house manufacturing capabilities and efforts; and availability of funding sufficient for its foreseeable and unforeseeable operating
expenses and capital expenditure requirements and Vor Bio s ability to continue as a going concern. These and other risks are described in greater detail under the caption Risk Factors included in Vor Bio s most recent annual
or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any
obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.